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Abstract 
 
The evolutionary events that cause colorectal adenomas to progress to carcinomas 
remain largely undetermined. Using multi-region genome/exome sequencing of 24 
benign and malignant colorectal tumours, we probe the evolutionary fitness landscape 
occupied by these neoplasms. Unlike carcinomas, advanced adenomas frequently 
harbour sub-clonal driver mutations that have not swept to fixation, and have relatively 
high genetic heterogeneity. The burden of single nucleotide alterations, including drivers, 
are similar between the two types of tumour. Carcinomas are instead distinguished from 
adenomas  by widespread aneusomies that are usually clonal and often accrue in a 
³punctuated´ fashion. Adenomas evolve across an undulating fitness landscape, 
whereas carcinomas occupy a sharper fitness peak, probably owing to stabilising 
selection. 
 
 
Introduction 
 
The classical adenoma-carcinoma sequence of colorectal tumorigenesis1 postulates that 
a conventional colorectal adenoma (CRA) LVLQLWLDWHGE\³WZRKLWV´DWAPC2,3, and typically 
progresses to colorectal cancer (CRC) through a stepwise accumulation of driver 
mutations such as KRAS and TP53 and deletion of chromosome 18q4. The evolutionary 
dynamics presumed to underlie this process comprise a series of selective sweeps to 
(near) fixation, each triggered by an elevation in sub-clone fitness through the 
occurrence of a new, positively-selected driver mutation5. In this model, progression to 
an invasive lesion (carcinoma)  is postulated to be prompted by the acquisition of a 
critical driver mutation burden, implying that adenomas and carcinomas should be 
distinguishable by specific driver mutations. CRCs can, however, develop without the full 
complement of driver mutations6,7, and some studies have suggested that sub-clonal 
evolution within established tumours is µHIIHFWLYHO\QHXWUDO¶8,9, questioning whether 
selective sweeps occur at all, especially in established CRCs. 
 
As part of a comprehensive assessment of colorectal tumour evolution, here we have 
attempted to re-DVVHVVWKHFODVVLFDOPRGHODQGRXWOLQHWKHHYROXWLRQDU\µILWQHVV
ODQGVFDSH¶RI&5$VDQG CRCs. The fitness landscape, a concept, first introduced by 
Sewall Wright in 193210, is an abstraction to help visualise the relationship between 
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genotypes and reproductive success (sub-clone fitness in this context). The X- and Y-
axeVFDQEHWKRXJKWRIDVWKHJHQRW\SHµVSDFH¶(simplified to 2 dimensions) that can be 
occupied by adenomas and carcinomas. The Z-axis or height is proportional to genotype 
fitness: peaks represent particularly fit genotypes, valleys less fit genotypes, and 
ridges/plateaux equally fit genotypes. Individuals sampled from a population are likely to 
occupy (local) fitness peaks, because less fit individuals have been removed by negative 
(purifying or stabilising) selection. Herein we search for the genotypes associated with 
the fitness peaks occupied by CRAs and CRCs and probe peak shapes by quantifying 
intra-tumour heterogeneity (ITH). Transitions around the landscape are measured using 
phylogenetic and molecular clock analyses.  These data provide a comprehensive 
understanding of the evolutionary trajectories underpinning the development of CRAs 
and CRCs. 
 
 
Results 
 
To map the evolutionary landscape of CRAs and CRCs, we performed multi-region 
whole-genome sequencing (WGS) or whole-exome sequencing (WES) on 2-16 regions 
(total 118) from 9 CRAs and 15 CRCs, each with constitutional DNA (Table S1 for 
sample details and S2 for sequencing statistics). Five CRCs, including four from Lynch 
syndrome patients, had microsatellite instability (MSI) owing to defective DNA mismatch 
repair, and these tumours were analysed as a distinct group unless otherwise stated. 
The remaining ten CRCs were microsatellite-stable (MSS) and of these, two were 
synchronous lesions from a single patient. Mutations in a subset of genes were validated 
using targeted molecular inversion probe sequencing (Online Methods). 
 
 
Somatic single nucleotide alterations do not define CRC fitness peaks 
 
We first assessed how somatic single nucleotide alterations (SNAs) defined the co-
ordinates of CRAs and CRCs in the fitness landscape. CRAs tended to have only slightly 
fewer SNAs than MSS CRCs CRAs: median exonic burden=94, 95% range [51-146]; 
MSS CRCs: median=130, 95% range [98-171]; p=0.29 Wilcoxon test; Figure 1A, Table 
S2). After sequencing coverage normalisation, the mutational frequency in CRAs 
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remained very similar to that of MSS CRCs (CRA; 4.1/Mb [3.3-4.9], MSS CRC; 4.2/Mb 
[2.9-6.4], p=0.9). 
 
Next we compared the burden of driver mutations across CRAs and CRCs, and included 
SNAs and indels, and also cnLOH and monosomy (chromosome loss) events that are 
NQRZQWRDFWDVµVHFRQGKLWV¶WRthe tumour suppressor genes APC and TP53, and also 
18q allelic loss/imbalance (Figure 1C-D and Table S3). The burden of tier 1 mutations, 
which we defined as likely pathogenic changes in known CRC driver genes (see Online 
Methods, Table S4), was not significantly different (CRAs: median=5 [2-9]; MSS CRCs: 
median=6 [2-8], p=0.9). We noted that the difference remained non-significant when 
comparing drivers across individual biopsies (p=0.19; Wilcoxon test).  Individual tier 1 
driver mutations were detected at similar frequencies across CRAs and CRCs, with the 
exception of TP53, which was more commonly mutated (possessing least one SNA, 
indel or copy change) in CRCs (Fisher test; p=0.005, see Figure 1D and Table S5). The 
frequency of tier 2 driver mutations (uncertain pathogenicity changes in CRC or pan-
cancer driver genes) was also similar in CRAs and MSS CRCs (CRAs: median=3 [2-4]; 
MSS CRCs: median=3 [1-7]; p=0.8). Several tier 2 driver mutations were specific to 
CRAs or CRCs, but most occurred infrequently; only KMT2C was notable, being mutated 
in 4 CRAs and no CRCs. The total driver mutation burdens (tier 1 and 2 combined; 
medians CRAs=7 [2-12]; CRCs=8 [3-15]; p=0.6; Figure 1C, Tables S3, S4) were also 
similar. Furthermore, when using an alternative definition of driver genes (the top 15 
genes mutated in MSS CRCs [excluding TTN], according to the TCGA publication7, 
Table S4b), the burdens remained not statistically different in CRAs and CRCs (CRAs: 
median=5 [2-7]; MSS CRCs: median=5.5 [2-9], p=0.7). 
 
In order to confirm the somewhat surprising finding that our CRAs and CRCs had similar 
mutational burdens, we accessed data from 481 primary CRCs (stages II-IV) and 55 
adenomas of similar type and size to those in our MSeq study. A single sample of each 
tumour had been sequenced by the S:CORT project (https://www.s-cort.org/) to a 
median depth of 150X using a panel that comprised the major CRC drivers and a 
number of other putative driver genes. Of the top 7 CRC driver genes by mutation 
frequency (APC, KRAS, BRAF, TP53, SMAD4, FBXW7, PIK3CA), the mean SNV burden 
was 2.1 in adenomas and 1.9 in CRCs (p=0.58, Wilcoxon test). In the complete set of 73 
CRC driver genes (https://www.intogen.org/search?cancer=COREAD) present in the 
panel, there was similarly no significant different between mutation burden in adenomas 
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(mean=11.1) and CRCs (mean=10.9; p=0.28). Thus, even in this large cohort analysed 
by different methods, the driver and total SNV burdens were indistinguishable between 
CRAs and CRCs.  
 
On the reasonable assumption that CRCs occupy a higher fitness peak than CRAs, our 
mutation burden data suggest that the relative co-ordinates of CRAs and CRCs in the 
evolutionary landscape are not principally determined by SNAs, and that the evolutionary 
µSURJUHVV¶from adenoma towards cancer is not simply measured by accumulated SNAs, 
including tier 1 driver mutations.  
 
 
Intra-tumour heterogeneity and phylogenetic analyses suggest that CRCs occupy 
sharper fitness peaks than CRAs 
 
To broadly assess the shape of the fitness peaks occupied by CRAs and MSS CRCs, we 
measured the degree of ITH in each tumour. Excluding tumours with only two regions 
sampled (see Online Methods), a median 56% [53-70%] of all CRA SNAs were ³sub-
clonal´ (variant not detected in all sampled regions). MSS CRCs had a significantly lower 
proportion of sub-clonal SNAs (45% [23-77%]; p=0.04; Figure 2 inset) than CRAs. The 
average pairwise genetic divergence between the regions of each tumour was then 
assessed following normalisation of sequencing coverage (Online Methods). CRAs 
showed significantly more divergence between biopsies than CRCs (CRA mean=2.0 
versus CRC=1.7, divergent SNAs/Mb; p<2x10-16; Figure S1A), despite having the same 
average mutation burden. The measured values of ITH were unaffected by the number 
of biopsies available from each neoplasm (Figure S1B-C). 
 
To further quantify ITH, we used SNAs to construct maximum parsimony phylogenetic 
trees (Figure 2). CRC topologies were often characterised by long trunks (variants 
ubiquitous across biopsies) with comparatively short branches and leaves (relatively few 
sub-FORQDOYDULDQWVWKXVDSSHDULQJµSDOP tree-shaped¶11. CRAs had proportionally 
shorter trunks, and thus longer branches/leaves than CRCs, albeit at borderline 
significance (average branch and leaf length as a proportion of the trunk: CRAs 82% 
versus MSS CRCs 50%; p=0.06; Figure 2, Table S6). The difference remained when the 
MSI+ CRCs were included in the analysis (CRAs 82% versus all CRCs 45%; p=0.05). 
CRAs are thus more genetically diverse than CRCs. 
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To investigate whether individual CRAs and CRCs occupied single or multiple fitness 
peaks, we compared the lengths of the phylogenetic tree branches/leaves. Large 
variations in branch length indicate that mutations accrue faster in some tumour regions 
than others, which can potentially be caused by selection on a new fitness peak. 
Average intra-tumour variation in relative branch/leaf length was generally low and 
similar across CRAs and CRCs (mean standard deviation: CRA 0.14 [0.06-0.24] versus 
CRC 0.2 [0.06-0.47]; p=0.68;  Figure 3, Table S6). Formal assessment of unbalanced 
tree topologies could only be performed on one tumour (carcinoma 6) as high numbers 
of samples are needed for sufficient power12.  Unbalanced trees occur when some 
ancestor clones produce more surviving lineages than another, another potential 
indicator of sub-clonal selection. We did not find any significant asymmetry in this single 
tumour analysis &ROOHVV¶WHVW, Yule model, p=0.3). Thus the available data were 
consistent with the idea that tumours occupied a single, potentially broad, fitness peak. 
 
The SNA-based ITH and phylogenetic analyses suggested that CRAs were more 
heterogeneous than CRCs, consistent with the former occupying a broader fitness peak, 
under which several distinct genotype-phenotype combinations could co-exist. The lower 
ITH in CRCs could also, however, reflect a more recent selective sweep with a genetic 
bottleneck during the transition from an adenoma, and/or that CRCs were more spatially 
mixed than CRAs, causing variants at sub-clonal frequency in multiple samples to 
appear truncal. We therefore directly sought evidence of stronger selection in CRCs by 
examining the ratio of non-synonymous to synonymous mutations on tumour trunks and 
branches/leaves. This showed a reduction in non-synonymous mutations on the 
branches/leaves of CRCs relative to their trunks (Wilcoxon sign rank test, p=0.01; Figure 
S2), but no such reduction for CRAs (p=0.9), possibly representing on-going positive 
subclonal selection in CRAs. On the reasonable assumption that positive selection acted 
on the phylogenetic trunk - the location of almost all tier 1 driver mutations ± together 
these results indicate that subclonal selection is absent (neutral dynamics) or weak 
within the established carcinoma, with possible negative (stabilising) selection also at 
play. 
 
 
Mutational processes are not detectably associated with fitness advantages 
 
 8 
 
Mutation signatures were identified de novo using the EMu program13. We recovered 
ageing, MSI-associated and molecular clock signatures14 (our Signatures A, B and C 
respectively), as expected (Figure S3A). Our Signature D, which resembles COSMIC 
Signature 17 (unknown aetiology, high CTT>CGT frequency15) was present at 
appreciable levels within carcinomas 2, 7, 9P and 10, with its activity often differing 
between the trunks and branches/leaves of the same lesion (Figure S3B,C). We 
explored whether signature D had any effect on sub-clonal evolution in CRCs with WGS. 
It appeared to increase the mutation burden in two CRCs 2 and 9P, but had no 
discernible effect on their evolution (details in Figure S3D). Carcinoma 9D, the 
synchronous partner of carcinoma 9P, showed low signature 17 activity, despite being 
located only 10cm apart in the bowel. These cancers also had different driver mutations, 
confirming that they essentially behaved as independent neoplasms, with no detectable 
effect of any shared microenvironment on mutagenic processes (Figure S4).  
 
 
Major driver mutations can be sub-clonal in CRAs, but are very rarely so in MSS CRCs 
 
Tier 1 driver mutations (defined above) were typically, but not always, clonal in CRAs, 
whereas in MSS CRCs drivers were more commonly clonal. However, these distributions 
were not significantly different between tumour types (CRAs=39/49, 80% versus 
CRCs=49/55, 89%; p=0.3). The clonal distributions of tier 2 clonal driver mutations were 
however, different; CRAs had significantly less clonal drivers than MSS CRCs 
&5$V YHUVXV&5&V )LVKHU¶VH[DFWWHVWS 7DEOH63). We 
noted that the clonality of tier 1 driver mutations was the same when using the second 
definition of driver mutations based on the TCGA publication7 (37/43, 86% versus 45/53, 
)LVKHU¶VH[DFWWHVWS!VHH Online Methods). The findings are consistent with a 
scarcity of sub-clonal expansions after the most recent common ancestor (MRCA) in 
CRCs. This trend seems to be similar in CRAs, though CRAs do show some evidence of 
sub-clonal driver mutations. 
 
We additionally noted, however, that the most frequently mutated CRC driver genes, 
apart from the probable tumour-initiating mutations in APC, were sub-clonal in at least 
one CRA. Notably in adenoma 2, KRAS Q61H and an ARID2 frameshift mutation were 
present in one region, which was separate from the three regions of this tumour that 
contained a TP53 E219X mutation. Adenoma 3 had a PIK3CA E545K mutation in two 
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tumour regions, GNAS R201H in another, and an AKAP9 frameshift in another. SMAD4 
R496H in adenoma 4 was also present in a single region. There was no evidence from 
the phylogenetic analysis that these proven driver mutations were associated with 
differential sub-clonal expansion, suggesting that their selective benefits were relatively 
modest (Figure 2). NRAS G60V and PIK3CA H1047R were present in both regions of 
adenomas 7 and 8 respectively, but were putatively sub-clonal since their corrected 
allele frequencies were significantly lower (p<0.05) than those of other driver mutations, 
suggesting that biopsies crossed sub-clonal boundaries. By contrast, only one sub-clonal 
mutation with high-confidence pathogenicity (CHD1 R619X in carcinoma 1) was found in 
the MSS carcinomas. There was no evidence for parallel evolution of sub-clones based 
on recurrent known or novel drivers (details not shown). 
 
We next we wished to relate the heterogeneity of mutational burdens to fundamental 
molecular processes. Immunohistochemistry for Ki-SUROLIHUDWLRQDQGȕ-catenin 
(activated Wnt-signalling; Figure S5; Online Methods) showed positive cell fractions of 
53% [2-80%] and 82% [3-97%] respectively, with considerable variability between and 
within CRCs (Table S7). Neither  .LQRUȕ-catenin expression was associated with 
regional SNA burden or ploidy (SNA burden, R2=0.2, p=0.2, ploidy, R2=0.9, p=0.08; 
Figure S5).  
 
 
Genetic and spatial relationships between CRC sub-clones 
 
In all CRCs, physical and phylogenetic distances between biopsies were strongly 
correlated (R2=0.81-0.93, p<10-4 for all carcinomas measured; Figure 4). The invasive 
edge of CRCs and central regions had similar mutational burdens (exonic SNAs, edge 
versus central; p=0.76). We looked further for sub-clonal mixing within the sampled 
regions of the MSS CRCs with WGS data by clustering of SNA cancer cell fractions 
across related samples, using a Dirichlet process-based model (Figure S6). Only 10% of 
biopsy samples showed evidence of 1 sub-clonal population. Whilst we do not exclude 
a degree of sub-clonal intermingling, these results suggest that, given the depth of the 
sequencing data, sub-clonal expansions broadly occurred in a spatially contiguous, 
uniform and discrete fashion.  
 
 
 10 
 
Copy number changes differ between CRAs and CRCs  
 
We next assessed whether somatic copy number alterations (CNAs) might define the 
fitness peaks occupied by CRAs and MSS CRCs. Every region of every tumour carried 
at least one CNA, including cnLOH (see Online Methods). In a combined analysis of all 
regions from each tumour, as expected, adenomas had fewer CNAs (number of discrete 
CNA segments >1Mb) than carcinomas16,17 (CRAs median=13 [7-11] versus CRCs 
median=40 [15-42], p=0.003; Figure 1B). Correspondingly, the overall average 
proportion of the genome disrupted by CNAs (FRS\QXPEHUDOOHOLFUDWLR) was 
higher in CRCs (CRCs, 72% versus CRAs, 40%; p=0.05; Figure 3). These data show 
that despite carrying similar SNA burdens, CRCs display higher CNA levels than CRAs. 
 
Driver CNAs are currently hard to identify with certainty in cancer18. In colorectal 
tumours, losses (deletions or cnLOH) on chromosomes 5q, 17p and 18q are often 
thought to be second hits involving tumour suppressors APC, TP53 and SMAD4 
respectively (although 18q loss is more common than SMAD4 mutation). The status of 
other recurrent changes ± such as 1q gain, 7 gain, 8p deletion, 13q gain and 20 gain ± 
as drivers or passengers is less clear. Many recurrent, and hence potential driver7, CNAs 
were present at significantly higher frequencies in CRCs compared to CRAs (Figure 3). 
Notably, 17p loss occurred in 9/10 MSS CRCs, but only 2&5$V)LVKHU¶VH[DFWWHVW, 
p=0.005), paralleling the TP53 SNA data. By comparison, loss at the APC locus (8/10 
CRCs versus 5/9 CRAs; p=0.35) and the SMAD4 locus (7/10 CRCs versus 4/9 CRAs; 
p=0.37; Figure 2) occurred at similar frequencies in both lesion types. 
 
Every tumour had at least 2 clearly sub-clonal CNAs (non-ubiquitous, present versus 
absent changes; Figure 3A) and no chromosome aberration was exclusively ubiquitous 
or sub-clonal across the tumours. Overall, 75% and 48% of gains were sub-clonal in 
CRAs and CRCs respectively (p=0.002), compared with 57% and 27% of losses/cnLOH 
(p=0.007; Figure S7). Thus, a greater proportion of CNAs were sub-clonal in CRAs than 
in CRCs.  
 
We compared the size distribution of large (>1Mb) CNAs in early (truncal) versus late 
(sub-clonal) tumour evolution. In CRCs, sub-clonal CNAs were smaller than ubiquitous 
CNAs (p<0.001 ; Figure S3C), but this difference was not present in CRAs (p=0.45).  The 
lower frequency of large CNAs later in evolutionary time in CRCs suggests that the 
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cancers have obtained a near-optimal level of aneuploidy, with further large-scale CNAs 
subjected to negative/stabilising selection. In adenomas, since the overall CNA burden is 
lower, new large CNAs may still be tolerated. 
 
 
MSS CRC evolution can involve either ³SXQFWXDWHG´or more gradual CNA acquisition 
 
Since CNAs were the principal genetic feature distinguishing CRAs and CRCs, we 
investigated their role in the transition between the benign and malignant fitness peaks. 
Utilising a similar strategy to Durink19 and Newman20 (details in Online Methods), we 
used the SNAs within informative chromosomal segments (copy number gains and 
cnLOH) as a molecular clock to time the occurrence of that CNA. SNAs present on a 
chromosome prior to gain, cnLOH or amplification increase in frequency (VAF) following 
the copy number change, whereas SNAs that accrue after the gain remain at their 
original, lower VAF. The ratio of higher to lower VAF SNAs therefore estimates the time 
of CNA occurrence.  
 
Sufficient SNAs for molecular clock analysis were only present in WGS data. Of the five 
MSS CRCs analysed by WGS, carcinomas 3, 9P and 10 showed a clustering of CNA 
timings shortly before the MRCA (Kolmogorov-Smirnov test against a uniform distribution 
of CNA timings, p<0.02 for all, Figure 5). A similar, borderline significant CNA cluster 
occurred in carcinoma 9D. Carcinoma 5 showed a more gradual accumulation of CNAs.  
 
Since the timing method GHPRQVWUDWHGDIRUPRI³SXQFWXDWHG´CNA evolution (rejection of 
null hypothesis of uniform accumulation), but did not distinguish between multiple gains 
of individual chromosomes and genome doubling followed by chromosomal gain or loss, 
we searched heuristically for evidence of genome doubling using a score  based on the 
number of chromosome centromeres present at copy number 4 or above, with extra 
weight for allelic balance (Figure S8). Based on this measure, all of the CRCs with 
significantly or borderline significantly clustered CNA timings (n=4) were genome-
doubled on this measure, as was the untimed carcinoma 8. The CNAs in these tumours 
are typically trisomies, judged to have arisen by chromosome (arm) loss subsequent to 
allele-balanced genome doubling. The other tumours (including carcinomas 1, 2, 4, 5, 6, 
7) were scored as non-genome-doubled. Sub-clonal genome doubling was present in 
one CRA (adenoma 2). This tumour carried a TP53 mutation in its genome-doubled 
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regions, and overall TP53 mutations (SNAs and/or CNAs) were associated with genome-
doubling in MSS CRCs ()LVKHU¶V([DFW7HVWp=0.018). In addition, genome-doubled 
cancer regions had higher Ki67 expression (see above; p=0.04; Figure S5), hinting at the 
existence of a selective benefit of doubling. 
 
 
The evolutionary landscape of microsatellite-unstable CRCs  
 
The overall SNA burden of the 5 MSI+ CRCs was, as expected, far higher than in MSS 
CRCs (Figure S9A). More pointedly, the number of tier 1 CRC driver mutations was also 
higher (median=12 [4-14]) than in MSS CRCs, median=3, p=0.042, Figure S9B), whilst 
CNA burden was lower (Figure S9C). Of note, in MSI+ CRCs, the great majority of driver 
SNAs were truncal, the number of sub-clonal tier 1 drivers was only a little greater 
(median=1 [0-7]) than in MSS CRCs, and the proportion of all sub-clonal SNAs was not 
significantly increased (median MSI+ CRCs 34% versus MSS CRCs 42%; p=0.13; 
Figure S9D). In phylogenetic analysis, neither the average branch/leaf length as a 
proportion of the trunk nor its variability differed significantly between MSI+ and MSS 
CRCs (Figure S9E). Our signature B (COSMIC signature 6) predominated in MSI+ 
CRCs, especially on the branches/leaves, but the other COSMIC MSI-associated 
signatures14 were not detected. Overall, the data suggest that MSI+ CRCs evolve in a 
similar way to MSS CRCs, albeit with some limited evidence of sub-clonal selection.  
 
 
Discussion 
 
Here we have contrasted the patterns of evolution in colorectal carcinomas and their 
classical adenomatous precursor lesion, and our data begin to reveal the shape of the 
fitness landscape over which CRCs grow. CRAs tend to evolve through acquisition of 
major driver mutations in genes such as APC, KRAS, TP53 and via 18q loss as per the 
Kinzler and Vogelstein model4. More recently discovered cancer driver mutations are 
also present in many adenomas (Table S3 & S4). In fact, CRAs can harbour mutations in 
any of the major CRC driver genes, but those mutations do not necessarily occur in a 
stereotypic order. Driver mutation acquisition also does not necessarily cause selective 
sweeps OHDGLQJWRµVWHSZLVH¶HYROXWLRQRIWKHWXPRXUFHOOSRSXODWLRQ, since sub-clones 
with additional major driver mutations may not displace sub-clones lacking those 
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mutations, but instead may co-exist in spatially discrete areas. It follows that many driver 
mutations probably confer a relatively small selective advantage. This is reflected in 
several observations in CRAs, including a relatively high level of genetic diversity (both 
SNAs and CNAs), variation in the major driver mutation complement in different regions 
of individual tumours, and phylogenetic trees with relatively long branches/leaves. It is 
even possible that SNA accumulation is not an essential feature of tumorigenesis prior to 
malignancy, and we speculate that carcinomas need not arise from the sub-clone with 
the greatest number of driver mutations, thus explaining why some CRCs have a very 
small driver mutation complement7.  
 
MSS CRCs have similar overall and major driver SNA burdens to precursor CRAs, but 
are less diverse, with longer phylogenetic tree trunks than branches/leaves. These 
findings may reflect the influence of several factors, including not only selective 
constraints, but also time from the MRCA after an additional selective sweep, ploidy, 
sample purity and genomic instability. They are, nevertheless, consistent with the notion 
that carcinomas are not simply µold adenomas¶ that have accumulated addition SNAs 
during a relatively protracted evolution. Overall, the lack of sub-clonal driver SNAs and 
reduction in non-synonymous SNAs on the branches and leaves of CRCs suggest that 
there is not strong positive sub-clonal selection for SNAs after the MRCA. CRAs on the 
other hand do show subclonal drivers and relatively high ITH together providing evidence 
of (perhaps relatively weak) subclonal selection. 
 
Although present in CRAs, large CNAs and genome doubling are much more common in 
CRCs. CNAs on CRC tree branches/leaves are smaller than those on trunks. Whilst 
negative or stabilising selection remains difficult to measure, this is consistent with the 
relatively low genetic diversity in CRCs, based on SNAs and large CNAs. For most MSS 
CRCs, a near-triploid karyotype seems optimal, either through genome doubling followed 
by loss of some chromosomes, or through a gain of chromosomes that mostly occurs 
within a putatively short time window between malignant progression and the MRCA. In 
each case, one or more selective sweeps seem to occur, rendering the driver SNAs and 
most CNAs clonal. We do not exclude additional positive selection for specific sub-clonal 
CNAs in CRCs, but this remains unproven and indeed our data showed no evidence of 
sub-clonal selection. Although every CRC had at least one sub-clonal CNA, we found no 
evidence of parallel CNA evolution. 
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In all our MSI+ cases, defective MMR and most major driver mutations arose on the 
phylogenetic trunk, and the relative branch/leaf length was similar to that of MSS CRCs. 
Although the sporadic MSI+ cancer had a low driver mutation burden, as expected if 
driven in part by a methylator phenotype21, its evolution was otherwise similar to the 
Lynch syndrome CRCs. We speculate that MSI+ CRCs experience either multiple 
selective sweeps driven by individual SNAs, or, more intriguingly, by co-occurring or 
epistatically acting non-canonical driver SNAs (such as CTNNB1, SOX9, NF1 and 
CASP8). 
 
A small number of ITH studies have been undertaken previously in CRC. Kim et al22 and 
Uchi et al23 performed multi-region WES of 5 primary and metastatic CRCs and 9 CRCs 
respectively, and Suzuki et al24 performed deep targeted sequencing of 799 genes in 
four CRCs. Similar to our study, these studies reported that major driver mutations, 
affecting APC, KRAS and TP53, were truncal, with the exception of PIK3CA. Uchi et al23 
also reported that large copy gains were common on the trunk of the evolutionary tree, 
with focal deletions on branches.  
 
Fewer studies of CRA evolution exist. Kim et al25 used WES to compare malignant and 
benign regions of 4 mixed cancer-in-adenoma polyps. They reported similar SNA 
burdens in cancer and adenoma regions, and thus suggested that the regions evolved in 
parallel, rather than the carcinoma progressing from a late adenoma. We note, however, 
that it is extremely hard to distinguish benign and malignant components of these 
lesions, since malignancy is defined not by cytology, but by invasion and hence the 
location of tumour cells. The different neoplastic components of such polyps may 
therefore, in reality, ERWKEHµFDQFHURXV¶)RUWKHVHUHDVRQVLQWKLVVWXG\ZHEDVHGRur 
comparison between advanced CRAs and CRCs that were distinct lesions. 
 
Previous work from our group10 examined single glands from 11 CRCs and 4 CRAs for 
CNAs, and for Ampliseq panels of SNAs that had been derived from bulk tumour WES. 
Although that manuscript and our present study had very different focuses, some of the 
ILQGLQJVDUHFRQVLVWHQW)RUH[DPSOHRQHIHDWXUHRIWKH³%LJ%DQJ´PRGHORIVXE-clonal 
intermixing expounded in the previous study is that after the MRCA, CRC sub-clones 
radiate outwards without notable differential sub-clonal expansion or selection of further 
advantageous variants; our present study is broadly consistent with those data. There 
are also, however, some differences between the studies that allow refinement of the 
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³%LJ%DQJ´PRGHO)RUH[DPSOHRXUFXUUHQWVWXG\ZKLFKEHQHILWVIURPWKHVLJQLILFDQWO\
increased genomic resolution of WGS/WES, emphasises that large sub-clones after the 
MRCA remain spatially restricted in CRCs and consequently that the previously 
observed, wiGHVSUHDGFORQDOµLQWHUPL[LQJ¶LQVRPH&5&V10 may reflect the shape, size, 
and boundary location of discrete sub-clones as well as outwards radiation of low 
frequency clones)XUWKHUPRUHZKLOVWWKH³%LJ%DQJ´ZDVbroadly consistent with ITH 
measured in CRAs, our present study finds that sub-clonal driver mutations in the 
absence of selective sweeps occur commonly in these tumours.   
 
In a study analogous to ours, Stachler et al26 exome-sequenced 5-11 samples of 
oesophageal carcinoma DQGLWVSUHFXUVRU%DUUHWW¶VRHVRSKDJXV%(from 5 patients. 
Comparing the two studies reveals both similarities and differences. BE is not a discrete 
WXPRXUDQGLVJHQHUDOO\DKLJKO\SRO\FORQDOOHVLRQUHIOHFWHGLQPXOWLSOH³LQLWLDWLQJ´GHOHWLRQ
mutations in CDKN2A and a series of clonal expansions without selective sweeps. By 
comparison, CRAs are discrete and probably have monoclonal origins usually caused by 
bi-allelic APC mutation, followed either by selective sweeps, or by polyclonal expansions 
reminiscent of BE. We note that in both BE27,28 and CRA, data are consistent with 
malignant progression sometimes occurring from a sub-clone that does not have the 
largest driver mutation burden. 
 
In summary, we have used measurements of intra-tumour heterogeneity to reveal the 
evolutionary trajectories of colorectal tumour cell populations across what appears to be 
a rather flat fitness landscape for adenomas, with a higher, sharper peak occupied by 
cancers. Our data refine the Fearon and Vogelstein model4 of CRC progression by 
showing that driver mutations do not necessarily lead to hard selective sweeps and that 
progression to CRC can involve punctuated evolution. 
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Figure legends 
 
Figure 1. Mutation burdens in CRAs and CRCs 
A.  CRAs tended to have slightly fewer exonic SNAs than CRCs but the difference was 
not significant. The average burden and 95% range across these different tumours is 
shown by the rightmost bars. B. The number of individual CNAs (as measured by the 
number of segmentations) is significantly greater in CRCs than CRAs (p=0.003, 95% 
range shown by bars).  C. SNA driver mutation burdens and allelic loss of 5q, 17p and 
18q, are shown for each tumour. A comparison of all events is show by the red bars, 
while tier 1 driver changes exclusively are shown in dark grey, with tier 2 in light grey. D. 
Distribution of canonical driver mutations across tumours. APC is the only ubiquitous 
driver event. There is no significant enrichment of cnLOH mutations as second hits to 
APC or TP53 mutations in adenomas compared to carcinomas (though TP53 is 
borderline). 
 
Figure 2. Phylogenetic analysis of CRAs and MSS CRCs 
Maximum parsimony construction of evolutionary trees.  For tumours with only two 
regional biopsies, truncal mutations were simply those shared between the regions. Tier 
1 driver mutations (Table S3) are shown, illustrating their enrichment on the trunks, 
especially in CRCs, indicating they are acquired early in evolutionary time. Phylogenetic 
trees showed were produced using all available SNAs. Tree shape robustness (branch 
support) was confirmed by bootstrapping. Branches had greater than 95% support 
unless otherwise stated (44/55 (80%) of branches had >95% support) . The most 
parsimonious trees are shown except in carcinoma 6, where one clade could not be 
resolved (A: green box). Left Bar chart: Ubiquitous SNAs (found in all regional biopsies 
and on the trunk of the phylogenetic tree) are compared with sub-clonal SNAs on the 
phylogenetic tree branches (non-ubiquitous, but present in >1 region) and leaf (present in 
only one region). CRAs have a smaller proportion of ubiquitous variants than CRCs. 
 
Figure 3. Copy number alterations in CRAs and MSS CRCs 
A. A genome-wide view of CNAs is shown for each region of CRAs (top) and CRCs 
(bottom). Cancers show a greater CNA burden than adenomas, and most CNAs are 
clonal in cancers, whereas CRAs show more frequent sub-clonal CNAs. Copy number 
LVVKRZQDV³SRO\VRP\´ B. The figure shows estimated ploidy and summarises the 
proportion of each tumour at different copy-states. Black bars show the range of biopsy 
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copy-numbers. C. Size distributions of ubiquitous and sub-clonal (branch and leaf) CNAs 
demonstrate the preference of CRCs to have larger events.  The colour-coding of copy 
number states (top right) applies to all panels. 
 
Figure 4. Geography of CRCs 
Photographs of the tumour specimens from histopathology departments are shown, with 
biopsy locations marked. The sporadic MSI+ cancer 4 is included here. The 
corresponding phylogenetic relationship between tumour regions is shown below the 
photograph of each tumour. The regression plots show pairwise physical and genetic 
separation for each biopsy from that cancer. There was a significant positive correlation 
between the phylogenetic (mutational) distance and physical distance in every case.  
 
Figure 5. CNA timing 
The plots show the CNA timing results for the six neoplasms with WGS data. For each 
tumour, the X-axis represents inferred evolutionary time to the MRCA, since tumour 
initiation (unit of measurement is SNAs accrued per unit time). Green dashed line is 
inferred from WKH³VHFRQGKLW´DWAPC (and thus likely represents the time of initiation of 
the adenoma). The upper panels show the accumulation of CNAs (red, arrowed line) 
relative to a steady accumulation (black, dashed line); p-values are derived from 
Kolmogorov-Smirnov tests of inferred CNA time versus a uniform accumulation. The 
lower panel shows the estimated times of driver mutations, where these could be 
derived, for individual CNAs by chromosome arm and type of change. Bars indicate 95% 
confidence intervals for CNA timing estimates.  
 
 
